To Assess the Anti-anginal Safety and Efficacy of Ivabradine in Subjects With Stable，Symptomatic Chronic Angina
Status:
Unknown status
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
Arms Assigned Interventions
Experimental: Ivabradine Ivabradine 5 mg twice a day for first 4 weeks and 7.5mg twice a day
when positive ETT and HR>60times/min or negative ETT and HR>80times/min of subjects.
Active Comparator: Atenolol Atenolol 12.5 mg twice a day for first 4 weeks and 25mg twice a
day when positive ETT and heard rate>60times/min or negative ETT and HR >80times/min of
subjects.